Pureos Bioventures has backed five spinouts so far from its multi-corporate-backed, biotech-focused fund.

Pureos Bioventures has backed five spinouts so far from its inaugural biotech-focused fund, which has reached its final close.

HBM Healthcare chipped in additional funding to bring University of Basel spinout Polyneuron's series A round to $39.7m.

Backed by Shanghai Fudan University previously, Virogin Biotech will invest the series C proceeds in its clinical drug programmes and securing industry partnerships.

Backed by Sinopharm Capital previously, Virogin Biotech will invest the series C proceeds in its clinical drug programmes and securing industry partnerships.

TriNetX had raised $102m in funding from investors including Merck & Co, Mitsui and Itochu before agreeing to a purchase by Carlyle.

Precision cancer drug developer Novellus boosted its funding total to $75.5m with a round featuring SR One and Novartis Venture Fund.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Two weeks after filing to go public, Grail has instead accepted an $8bn acquisition offer from Illumina, which had spun off the cancer diagnostics technology developer five years ago.

Unnamed corporates have provided capital for Panlin’s $148m fund that will focus on healthcare, digital transformation and smart hardware.